A Moxifloxacin-based Regimen for the Treatment of Recurrent, Drug-sensitive Pulmonary Tuberculosis: An Open-label, Randomized, Controlled Trial.

ABSTRACT:

Background

The substitution of moxifloxacin for ethambutol produced promising results for improved tuberculosis treatment outcomes.

Methods

We conducted an open-label, randomized trial to test whether a moxifloxacin-containing treatment regimen was superior to the standard regimen for the treatment of recurrent tuberculosis. The primary and secondary outcomes were the sputum culture conversion rate at the end of 8 weeks and the proportion of participants with a favorable outcome, respectively.

Results

We enrolled 196 participants; 69.9% were male and 70.4% were co-infected with human immunodeficiency virus (HIV). There was no significant difference between the study groups in the proportion of patients achieving culture conversion at the end of 8 weeks (83.0% [moxiflo

SUBMITTER: Perumal R 

PROVIDER: S-EPMC10686245 | biostudies-literature | 2020 Jan

REPOSITORIES: biostudies-literature